EFdA-TP is primarily used in the field of antiviral research, particularly in the development of treatments for HIV. It functions as a potent nucleoside reverse transcriptase inhibitor (NRTI), effectively blocking the replication of the virus by interfering with the reverse transcriptase enzyme. This makes it a promising candidate for antiretroviral therapy, especially in cases where resistance to other drugs has developed. Its high efficacy and low toxicity profile have garnered significant attention in preclinical studies, suggesting its potential for inclusion in future HIV treatment regimens. Additionally, EFdA-TP is being explored for its application in long-acting formulations, which could reduce the frequency of dosing and improve patient adherence to treatment protocols.